%0 Journal Article %1 Personeni.2008 %A Personeni, N. %A Fieuws, S. %A Piessevaux, H. %A De, Hertogh G. %A De, Schutter J. %A Biesmans, B. %A De, Roock W. %A Capoen, A. %A biec Rychter, M. %A van Laethem, J. L. %A Peeters, M. %A Humblet, Y. %A Van, Cutsem E. %A Tejpar, S. %D 2008 %J Clin.Cancer Res. %K 80 Adult Aged Antibodies Colorectal Disease-Free Dosage Female Fluorescence Gene Genes Genetic Humans Hybridization In Male Markers Middle Monoclonal Mutation Neoplasms Prognosis Research Situ Survival analysis and drug erbB-1 genetics over response therapeutic therapy use %N 18 %P 5869-5876 %T Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study %U PM:18794099 %V 14 %X PURPOSE: To evaluate the usefulness and the pitfalls inherent to the assessment of the epidermal growth factor receptor (EGFR) gene copy number (GCN) by fluorescence in situ hybridization (FISH) for outcome prediction to cetuximab in metastatic colorectal cancer. The value of testing KRAS mutation status, in addition to EGFR GCN, was also explored. EXPERIMENTAL DESIGN: FISH analysis of 87 metastatic colorectal cancer patients treated with cetuximab was done, recording individual GCN per cell and using different samples per tumor. Performances of published cutoff points and different summaries of EGFR GCN distribution were assessed for response prediction. RESULTS: In our data set, two published cutoff points performed less well than in their training set, yielding positive predictive values and negative predictive values between 40.0% and 48.3% and between 81.0% and 86.5%, respectively. Among summaries of GCN distribution explored, mean and right-tailed distribution of GCN yielded the

@article{Personeni.2008, abstract = {PURPOSE: To evaluate the usefulness and the pitfalls inherent to the assessment of the epidermal growth factor receptor (EGFR) gene copy number (GCN) by fluorescence in situ hybridization (FISH) for outcome prediction to cetuximab in metastatic colorectal cancer. The value of testing KRAS mutation status, in addition to EGFR GCN, was also explored. EXPERIMENTAL DESIGN: FISH analysis of 87 metastatic colorectal cancer patients treated with cetuximab was done, recording individual GCN per cell and using different samples per tumor. Performances of published cutoff points and different summaries of EGFR GCN distribution were assessed for response prediction. RESULTS: In our data set, two published cutoff points performed less well than in their training set, yielding positive predictive values and negative predictive values between 40.0% and 48.3% and between 81.0% and 86.5%, respectively. Among summaries of GCN distribution explored, mean and right-tailed distribution of GCN yielded the }, added-at = {2010-02-05T11:28:39.000+0100}, author = {Personeni, N. and Fieuws, S. and Piessevaux, H. and De, Hertogh G. and De, Schutter J. and Biesmans, B. and De, Roock W. and Capoen, A. and biec Rychter, M. and van Laethem, J. L. and Peeters, M. and Humblet, Y. and Van, Cutsem E. and Tejpar, S.}, biburl = {https://www.bibsonomy.org/bibtex/22d1ca63c22c53f0332faa42e1895232c/kanefendt}, interhash = {0e86e74408dfe96c94ab2ceb8026ae21}, intrahash = {2d1ca63c22c53f0332faa42e1895232c}, journal = {Clin.Cancer Res.}, keywords = {80 Adult Aged Antibodies Colorectal Disease-Free Dosage Female Fluorescence Gene Genes Genetic Humans Hybridization In Male Markers Middle Monoclonal Mutation Neoplasms Prognosis Research Situ Survival analysis and drug erbB-1 genetics over response therapeutic therapy use}, number = 18, pages = {5869-5876}, timestamp = {2010-02-05T11:28:49.000+0100}, title = {Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study}, url = {PM:18794099}, volume = 14, year = 2008 }